A simple choice for glaucoma

Rocklatan® and Rhopressa® are prescription medications for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

Please see pages 12–15, 22, and 23 for IMPORTANT SAFETY INFORMATION.
**Understanding glaucoma**

**How should I take care of my glaucoma?**

Glaucoma is an eye disease caused by an increase of fluid, which raises pressure (called intraocular pressure or IOP) in the eye. It can be controlled but not cured. If untreated, it can lead to reduced vision and blindness. So if your eye doctor diagnoses you with glaucoma, it’s essential to take the medication he or she prescribes—as directed—and get regular checkups.

**Why me?**

Many people with glaucoma ask why they have this condition. We have learned that there are a number of risk factors. For example, people are at higher risk if a family member has glaucoma. African Americans are more than four times more likely to develop glaucoma or ocular hypertension (OHT) than Caucasians, and people over 60 years of age are at increased risk. If you have any of these risk factors (or other risk factors associated with glaucoma), it’s important to see an eye doctor to be screened for glaucoma.

---

**How could increased pressure harm my vision?**

When the fluid that normally fills your eye fails to drain properly, it builds up pressure and pushes against the optic nerve. The pressure against the optic nerve can damage it and lead to loss of vision. If left untreated, this loss of vision can get even worse over time.

**A unique way to lower eye pressure**

Your doctor will measure your IOP and decide how much it needs to be lowered. He or she will also suggest different methods to reduce it. This brochure will introduce you to two prescription eye drops that work in a unique way to help lower eye pressure and reduce the risk of vision loss.
Ask your eye doctor if Rocklatan® or Rhopressa® is right for you

Below are some questions you can ask your eye doctor to see if there are different options to lower IOP.

If you’re already on a therapy other than Rhopressa® or Rocklatan®, you might ask:

“If you prescribe once-daily Rocklatan® or Rhopressa® for me, what side effects should I expect? Is there a better time of day to take these eye drops?”

“Are there any ways I can save on my Rocklatan® or Rhopressa® prescription?”

IMPORTANT SAFETY INFORMATION

Contraindications
None.

Warnings and Precautions
ROCKLATAN® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as ROCKLATAN® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

For complete Rocklatan® IMPORTANT SAFETY INFORMATION, please see pages 12-15.
Rocklatan® for open-angle glaucoma or ocular hypertension

A unique, once-daily eye drop that helps reduce eye pressure through two different pathways

- Learn why Rocklatan® provides better control than the most prescribed eye drop, latanoprost
- Learn how to get the most out of your once-daily treatment
- Learn a simple way to get your medicine
- Use your Co-Pay Card for savings
58% of patients taking Rocklatan® achieved a target IOP of 16 or less

INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

The medicines in Rocklatan® eye drops are thought to open two different channels for excess fluid to leave your eye, with the result that your eye pressure (IOP) is lowered more than with either of these two medicines alone.

One of these medicines, netarsudil, is unique: it’s specifically designed to reduce pressure by releasing excess fluid through the trabecular meshwork, featured in blue on the next page.

The other medicine, latanoprost, is the most widely used medicine for reducing eye pressure. It releases fluid through the uveoscleral pathway, featured in green on the next page.

Rocklatan® does all of this with just a single drop that you take once daily.

Reducing your eye pressure and keeping it low is the recommended way to help preserve your vision.

The most frequent side effect reported in clinical studies was red eye. Other reported side effects included mild pain upon instillation, small deposits on the outer surface of the eye, and broken blood vessels on the white of the eye. These side effects were non–sight threatening.
What to expect with Rocklatan®

Rocklatan® was proven safe and tolerable in clinical trials, with the majority of side effects graded as mild.

The most common side effect was eye redness or mild pain upon instillation. Eighty percent of the time, when eye redness occurred, it was sporadic. Eye redness was graded as mild 90% of the time, and it did not get worse over time.

Do not stop taking your eye drops unless your doctor tells you to stop.

Contact your doctor immediately if you experience any sudden change in your vision.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION
See pages 12–15 for IMPORTANT SAFETY INFORMATION.

For full Prescribing Information, please visit Rocklatan.com
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used together with other eye drops to lower high eye pressure/IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

IMPORTANT SAFETY INFORMATION
Contraindications
None.

Warnings and Precautions
ROCKLATAN® contains latanoprost, which may cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as ROCKLATAN® is administered, and eye color changes are likely to be permanent. Eyelash changes are usually reversible upon discontinuation of treatment.

ROCKLATAN® should be used with caution and may cause inflammation inside the eye or make existing inflammation worse.

ROCKLATAN® may cause macular edema (swelling of the macula) and should be used with caution in patients without a natural lens, in patients with a torn posterior lens capsule who have an artificial lens implant, or in patients with known risk factors for macular edema.

ROCKLATAN® should be used with caution in patients with a history of herpetic keratitis and not used in patients with active herpes simplex keratitis.

Continued on the following page
WARNINGS AND PRECAUTIONS

Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to using ROCKLATAN®. Contact lenses can be reinserted 15 minutes following administration of ROCKLATAN®.

If you have eye surgery, eye trauma or infection, or develop any eye reactions, immediately consult with your physician about continuing treatment with ROCKLATAN®.

ADVERSE REACTIONS

The most common side effect for ROCKLATAN® in controlled clinical studies were red eyes (59%). Five percent of patients discontinued therapy due to red eyes. Other common side effects were pain upon instillation of eye drop (20%), small deposits on the outer surface of the eye (corneal verticillata) (15%), and broken blood vessels (11%).

Adverse reactions continued

Eye itching, visual acuity reduced, excessive tearing, eye discomfort upon administration of eye drop, and blurred vision were reported in 5-8% of patients.

Be sure to contact your doctor if you have any questions.

FOR FULL PRESCRIBING INFORMATION FOR ROCKLATAN® SOLUTION, PLEASE VISIT ROCKLATAN.COM

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

NOTES:
Get started with once-daily Rhopressa®

- Learn why this medicine is unique
- Learn how to get the most out of your once-daily treatment
- Learn a simple way to get your medicine
- Use your Co-Pay Card for savings
Rhopressa® is a treatment for patients with open-angle glaucoma or ocular hypertension

Rhopressa® is believed to control IOP in a unique way, lowering elevated eye pressure by draining excess fluid through the main channel of your eye, the trabecular meshwork, featured in yellow on the next page.

Reducing eye pressure may reduce the risk of disease progression.

Ask your healthcare provider if you have questions.

The most frequent side effect reported in clinical studies was red eye. Other reported side effects included mild pain upon instillation, small deposits on the outer surface of the eye, and broken blood vessels on the white of the eye. These side effects were non–sight threatening.

INDICATION AND USAGE
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
What to expect with Rhopressa®

Rhopressa® was proven safe and tolerable in clinical trials, with the majority of side effects graded as mild.

The most common side effect was eye redness. Eighty percent of the time, when eye redness occurred, it was mild and sporadic. The redness did not tend to get worse over time.

Do not stop taking your eye drops unless your doctor tells you to stop.

Contact your doctor immediately if you experience any sudden change in your vision.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.

IMPORTANT SAFETY INFORMATION
See pages 22–23 for IMPORTANT SAFETY INFORMATION.

For full Prescribing Information, please visit Rhopressa.com
RHOPRESSA®
IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE
RHOPRESSA® (netarsudil ophthalmic solution) 0.02% is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Bacterial Keratitis: Avoid allowing the tip of the bottle to touch the eye to avoid bacterial eye infection which has been reported with the use of multiple-dose containers of topical ophthalmic products.

Contact Lenses: Contact lenses should be removed prior to using RHOPRESSA® and may be reinserted 15 minutes following its administration.

ADVERSE REACTIONS
The most common ocular adverse reaction observed in controlled clinical studies with RHOPRESSA® dosed once daily were red eyes, in 53% of patients. Six percent of patients discontinued therapy due to red eyes. Other common (approximately 20%) adverse reactions were: small deposits on the outer surface of the eye, mild pain upon instillation, and broken blood vessels on the white of the eye. Instillation site redness, corneal staining, blurred vision, increased tearing, redness of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The small deposits on the outer surface of the eye seen in RHOPRESSA®-treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most small deposits on the outer surface of the eye resolved upon discontinuation of treatment.

Please see full RHOPRESSA® Prescribing Information at Rhopressa.com

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Rocklatan® or Rhopressa® should be taken once daily in the evening

Important tips:

- Do not stop taking your eye drops unless your doctor tells you to stop
- The recommended dosage is one drop in the affected eye(s) once daily in the evening
- Take Rocklatan® or Rhopressa® at the same time each night. This will help you remember to take your medicine each day and will help simplify your treatment routine
- Avoid touching the tip of the container to the eyes, fingers, or any surface to avoid contamination of the solution
- If you miss a dose, just take it the next night
- Storage: Bottles of Rocklatan® must be protected from light. Bottles of Rocklatan® and Rhopressa® must be refrigerated until opened
- Do not take more than one drop per day in each eye
- Rocklatan® and Rhopressa® can also be used with other eye drop treatments—just wait at least 5 minutes before using another medicine
- Contact lenses should be removed before taking Rocklatan® or Rhopressa® and may be reinserted 15 minutes after administration

Record My Eye Pressure

Date_________ Eye Pressure___________

Date_________ Eye Pressure___________

Date_________ Eye Pressure___________

Date_________ Eye Pressure___________

Date_________ Eye Pressure___________

Date_________ Eye Pressure___________
Making it easier for you to get Rocklatan® or Rhopressa®

Start Saving on Rocklatan® or Rhopressa® Today!

Eligible patients may Pay As Little As $25* for a 30-day or 90-day prescription.

That's less than $9 per month for a 90-day prescription with savings offer.

*Restrictions apply. Patients with federal or state prescription coverage, such as Medicare or Medicaid, are not eligible.

You are likely to have commercial prescription benefit if:

- You are under 65
- Your employer or your spouse’s employer provides your insurance
- You are retired and your former employer provides your insurance
- You signed up for commercial insurance
Terms and Conditions

**Patient Instructions:** In order to redeem this offer you must have a valid prescription for ROCKLATAN® or RHOPRESSA®. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients who are enrolled in a state or federally funded prescription insurance program, such as Medicare or Medicaid, are excluded. Patients with questions about the ROCKLATAN® or RHOPRESSA® Savings offer should call 1-844-807-9706.

**Eligible commercially insured patients** may pay as little as $25 per 30-day, 60-day, or 90-day supply. Patient pay amount may vary dependent upon commercial insurance coverage for ROCKLATAN® or RHOPRESSA®. Maximum savings limit applies; patient out-of-pocket expense may vary. Offer valid up to 12-month qualifying prescriptions.

**Pharmacist instructions:** Submit the claim to the primary commercial insurance company first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code. For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk 1-800-433-4893.

Terms and Conditions continued on the next page
Terms and Conditions continued

Restrictions: This offer is valid for eligible residents of the United States only. This offer is void in U.S. territories including, but not limited to, Puerto Rico. Offer not valid for prescriptions reimbursed under Medicare, a Medicaid drug benefit plan, TRICARE, CHAMPUS or other federal or state health programs. Offer may not be combined with any savings, discount, trial or similar offer for the same prescription. No other purchase is necessary. Coupon is not insurance. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, trade, or counterfeit this offer. This offer is not transferable. Void where prohibited by law. Absent a change in Massachusetts law, for Massachusetts residents only, this offer will expire on December 31, 2021. Program managed by ConnectiveRx on behalf of Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. reserves the right to rescind, revoke or amend this offer without notice at any time.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Start Saving on Rocklatan® or Rhopressa® Today!

Patient Instructions: In order to redeem this offer you must have a valid prescription for ROCKLATAN® or RHOPRESSA®. This offer may not be redeemed for cash. By using this offer, you are certifying that you meet the eligibility criteria and will comply with the terms and conditions described in the Restrictions section below. Patients who are enrolled in a state or federally funded prescription insurance program, such as Medicare or Medicaid, are excluded. Patients with questions about the ROCKLATAN® or RHOPRESSA® Savings offer should call 1-844-807-9796.

Eligible commercially insured patients may pay as little as $25 per 30-day, 60-day, or 90-day supply. Patient pay amount may vary dependent upon commercial insurance coverage for ROCKLATAN® or RHOPRESSA®. Maximum savings limit applies; patient out-of-pocket expenses may vary. Offer valid up to 12-month qualifying prescriptions.

Pharmacist Instructions: Submit the claim to the primary commercial insurance company first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code. Reimbursement will be received from CHANGE HEALTHCARE.

For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk 1-800-433-4893.

Restrictions: This offer is valid for eligible residents of the United States only. This offer is void in U.S. territories including, but not limited to, Puerto Rico. Offer not valid for prescriptions reimbursed under Medicare, a Medicaid drug benefit plan, TRICARE, CHAMPUS or other federal or state health programs. Offer may not be combined with any savings, discount, trial or similar offer for the same prescription. No other purchase is necessary. Coupon is not insurance. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, trade, or counterfeit this offer. This offer is not transferable. Void where prohibited by law. Absent a change in Massachusetts law, for Massachusetts residents only, this offer will expire on December 31, 2021. Program managed by ConnectiveRx on behalf of Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. reserves the right to rescind, revoke or amend this offer without notice at any time.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
Start Saving on Rocklatan® or Rhopressa® Today!

Follow This Easy Step

Provide the savings card above to the pharmacist with your prescription for either Rocklatan® or Rhopressa®.

For complete Terms and Conditions, please see pages 28–30.

To learn more about Rocklatan®, please visit www.Rocklatan.com

To learn more about Rhopressa®, please visit www.Rhopressa.com

Rocklatan® is a registered trademark of Aerie Pharmaceuticals, Inc.
Rhopressa® is a registered trademark of Aerie Pharmaceuticals, Inc.
©2021 Aerie Pharmaceuticals, Inc. All rights reserved. US-ROC-P-0008 01/21